Advanced Non-small-cell Lung Cancer Clinical Trial
Official title:
A Randomized Controlled, Multi-center Phase III Clinical Trial of AK112 Versus Pembrolizumab as First-line Treatment for PD-L1-Positive Locally-Advanced or Metastatic Non-Small Cell Lung Cancer
This trial is a Phase III study. All patients are stage IIIB/C (unsuitable for radical therapy) or IV non-small cell lung cancer(NSCLC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1. The purpose of this study is to evaluate the efficacy and safety of AK112 comparing Pembrolizumab in subjects with advanced NSCLC whose tumors have a programmed cell death-ligand 1 (PD-L1) Tumor Proportion Score (TPS) greater than or equal to 1%.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05435274 -
Phase 1/2 Study of HS-10376 in Patients With Non-Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
| Enrolling by invitation |
NCT05192681 -
Tislelizumab as Cross-line Treatment for Advanced NSCLC
|
Phase 2 | |
| Not yet recruiting |
NCT04733521 -
A Phase 1/2 Study of SC-43 in Combination With Cisplatin
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04455984 -
Multimodality Treatment Including Curative Resection of Advanced NSCLC
|
||
| Completed |
NCT05380908 -
Brain Metabolic Network of PET in Patients With Advanced Non-Small Cell Lung Cancer
|
||
| Recruiting |
NCT05904379 -
AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer
|
Phase 1/Phase 2 |